Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1NET 1Gynecologic 1Genitourinary 1Gastrointestinal 1Endocrine 1Breast 1

Conditions

Carcinoma, Renal Cell 11Prostatic Neoplasms 2Neoplasm Metastasis 2Vulvar Neoplasms 1Sarcoma 1Ovarian Neoplasms 1Neuroendocrine Tumors 1Gallbladder Neoplasms 1Disease Progression 1Clear-cell metastatic renal cell carcinoma 1Carcinoma, Neuroendocrine 1Breast Neoplasms 1Bile Duct Neoplasms 1

Interventions

fludarabine 3Radiotherapy 3Cyclophosphamide 3entinostat 2aldesleukin 2aflibercept 2Trastuzumab 2Nivolumab 2Adoptive Transfer 2trastuzumab deruxtecan 1tivozanib 1tipifarnib 1rocakinogene sifuplasmid 1pembrolizumab 1oncogene protein E7, Human papillomavirus type 16 1durvalumab 1bintrafusp alfa protein, human 1atezolizumab 1Vorinostat 1VGX-3100 1Specimen Handling 1Ritonavir 1Radiation 1Quality of Life 1Patient Reported Outcome Measures 1Octreotide 1Observation 1Molecular Diagnostic Techniques 1Magnetic Resonance Spectroscopy 1MEDI0457 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Vulvar Neoplasms × tivozanib × Genitourinary × Clear all
NCT05000294 2026-06-05

Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types

University of Florida

Phase 1/2 Recruiting
29 enrolled
BreastEndocrineGastrointestinalGenitourinaryGynecologicNETSarcoma

Bile Duct Neoplasms, Breast Neoplasms, Gallbladder Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Sarcoma, Vulvar Neoplasms, Carcinoma, Neuroendocrine, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡